盐酸吡柔比星(Pirarubicin Hydrochloride) - 药物靶点：DNA x Top II_在研适应症：胃癌，急性白血病，膀胱癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Adriamycin, tetrahydropyranyl、Pirarubicin、Tetrahydropyranyl doxorubicin

+ [14]

靶点

DNA x Top II

作用机制

DNA抑制剂(DNA抑制剂)、Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

肿瘤免疫系统疾病消化系统疾病+ [4]

在研适应症

胃癌急性白血病膀胱癌+ [7]

非在研适应症-

原研机构

Meiji Seika Pharma Co., Ltd.

在研机构

MicroBiopharm Japan Co., Ltd.

Meiji Seika Pharma Co., Ltd.

深圳万乐药业有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1988-03-29),

急性白血病膀胱癌乳腺癌+ [6]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C32H38ClNO12

InChIKeyZPHYPKKFSHAVOE-YZIXBPQXSA-N

CAS号95343-20-7

关联

29

项与盐酸吡柔比星相关的临床试验

NCT06714383 / Recruiting临床2期IIT

A Prospective Randomized Phase Ⅱ Study of Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.

开始日期2024-11-13

申办/合作机构

北京大学人民医院

NCT05287308 / Not yet recruitingN/AIIT

Adjuvant AC Followed by Albumin-bound Paclitaxel Versus AC Followed by Taxanes in Breast Cancer: a Prospective, Multi-center, Real-world Study

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.

开始日期2022-03-01

申办/合作机构

中国医学科学院

[+1]

NCT04522310 / CompletedN/A

ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis

COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.

开始日期2020-07-07

申办/合作机构

Centre Hospitalier de Lens

100 项与盐酸吡柔比星相关的临床结果

登录后查看更多信息

100 项与盐酸吡柔比星相关的转化医学

登录后查看更多信息

100 项与盐酸吡柔比星相关的专利（医药）

登录后查看更多信息

1,232

项与盐酸吡柔比星相关的文献（医药）

2024-12-31·International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model

Article

作者: Ye, Zhangqun ; Xu, Ying ; Sun, Guoliang ; Chen, Wanyi ; Liu, Chunyan ; Zhao, Kai ; Yu, Jie ; Yang, Tiantian ; Hu, Poyi ; Luo, Wanru ; Chen, Guoyi ; Zhang, Tingke ; Zhang, Huiping ; Wu, Yuqing ; Li, Huaibiao ; Liu, Haoran

OBJECTIVE:

This study aimed to evaluate the combined efficacy of hyperthermia and chemotherapy using a bladder cancer organoid model and to explore hyperthermia-related molecular pathways.

METHOD:

Tumor organoids were generated by embedding RT4 bladder cancer cells into Matrigel. The resulting organoids were treated with pirarubicin or gemcitabine at 37 °C or 42 °C. Proliferation was determined by Ki67 immunofluorescence staining, and apoptosis was assessed using a TdT-mediated dUTP nick end labeling (TUNEL) assay. RNA sequencing was used to identify the differentially expressed genes.

RESULTS:

Bladder cancer organoids were successfully established and exhibited robust proliferative abilities. Treatment with gemcitabine or pirarubicin under hyperthermic conditions caused pronounced structural damage to the organoids and increased cell death compared to that in the normothermically treated group. Furthermore, Ki67 labeling and TUNEL assays showed that the hyperthermia chemotherapy group showed a significantly reduced proliferation rate and high level of apoptosis. Finally, RNA sequencing revealed the IFN-γ signaling pathway to be associated with hyperthermia.

CONCLUSION:

Overall, hyperthermia combined with chemotherapy exerted better therapeutic effects than those of normothermic chemotherapy in grade 1-2 non-muscle-invasive bladder cancer, potentially through activation of the IFN-γ-JAK-STAT pathway.

2024-12-01·INTERNATIONAL IMMUNOPHARMACOLOGY

Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency

Article

作者: Cui, Nai-Peng ; Feng, Decheng ; He, Yanqiu ; Wang, Tingting ; Su, Chenghan ; Zhang, Ruobing ; Shi, Jian-Hong ; Li, Jing-Hua ; Wang, Yaqiong ; Qin, Yan ; Bao, Tong

BACKGROUND:

Triple-negative breast cancer (TNBC) is prone to relapse due to the lack of effective therapeutic targets. Macrophages are the most abundant immune cells in the tumor microenvironment (TME) of breast cancer. Targeting the cross-talk between macrophages and cancer cells provides a more efficient strategy for anti-tumor therapy. Toll-like receptors (TLRs) are important players involved in macrophage activation, and TLR agonists are known to play roles in cancer therapy. However, the combination strategy of TLR agonists with chemotherapy drugs is still not well characterized.

METHODS:

RT-PCR and Western blot were used to detect the expression of TLRs. The communication between breast cancer cells and macrophages were determined by co-culture in vitro. Tumor cells proliferation and migration were investigated by MTT assay and scratch wound assay. The effects of drug combinations and toxic side effects were assessed by immunohistochemistry and Hematoxylin & Eosin staining.

RESULTS:

Expression of TLR3 and TLR4 were lower in breast tumor tissues compared with adjacent normal tissues. Patients with higher TLR3 or TLR4 expression levels had a better prognosis than those with lower expression levels. TLR3/4 expression was significantly inhibited when breast cancer cells MDA-MB-231 and E0771 were conditioned-cultured with macrophages in vitro and was also inhibited by pirarubicin (THP). However, the combination of TLR agonists and THP could reverse this response and inhibit the proliferation and migration of breast cancer cells. Additionally, this combination significantly reduced the tumor volume and weight in the murine model, increased the expression of TLR3/4 in mouse breast tumors.

CONCLUSIONS:

Our results provide new ideas for the combination strategy of THP with TLR agonists which improves prognosis of breast cancer.

2024-11-18·ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE

Specific Efficacy and Safety in the Clinical Application of Anlotinib for Thymic Carcinoma.

Article

作者: Ning, Ruiling ; Liu, Qianfei ; He, Jianbo ; Zeng, Aiping

Background:

Thymic carcinoma is a rare and aggressive malignancy characterized by high invasiveness, poor prognosis, and limited treatment options post-chemotherapy failure. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in inhibiting tumor growth and metastasis, suggesting potential as an adjunctive therapy in this challenging clinical setting.

Objective:

To evaluate the efficacy and safety of Anlotinib as a potential treatment option for thymic carcinoma post-chemotherapy failure, assessing its impact on tumor progression and patient survival outcomes.

Case Presentation:

A 46-year-old female presented with a left supraclavicular mass persisting for one month. Percutaneous needle biopsy of the left mediastinal mass confirmed thymic carcinoma, specifically lowly differentiated squamous cell carcinoma.

Management:

The patient underwent sequential treatment modalities, including first-line therapy, comprising four cycles of cisplatin + paclitaxel, followed by subsequent radiotherapy to the chest and neck. It was followed by second-line therapy involving six cycles of cyclophosphamide + pirarubicin + nedaplatin and third-line therapy consisting of four cycles of gemcitabine and nedaplatin. Notably, fourth-line therapy with Anlotinib monotherapy resulted in a progression-free survival of 10 months.

Outcome:

Anlotinib emerges as a potential therapeutic option for thymic carcinoma post-chemotherapy failure. However, further validation through preclinical investigations and clinical trials is warranted.

Conclusion:

Despite its limited ability to rapidly reduce tumor size, Anlotinib demonstrates efficacy in inhibiting neovascularization and impeding tumor progression and metastasis, thereby maintaining long-term tumor stability. It highlights its potential as a valuable adjunctive therapy in the management of thymic carcinoma.

11

项与盐酸吡柔比星相关的新闻（医药）

2024-01-24

·生物探索

Natl Sci Rev | 哈尔滨医科大学徐万海等团队合作开发新的纳米颗粒，诱导线粒体病样损伤靶向治疗膀胱癌

引言线粒体病引起的三磷酸腺苷(ATP)消耗已被认为是控制肿瘤生长的有力途径。然而，在复杂的生物环境下，ATP的选择性封存或耗竭仍然是一个巨大的挑战。2024年1月22日，哈尔滨医科大学徐万海、国家纳米科学技术中心王浩、武汉理工大学程冬炳共同通讯在National Science Review（IF=21）在线发表题为“Inducing mitochondriopathy-like damages by transformable nucleopeptide nanoparticles for targeted therapy of bladder cancer ”的研究论文，该研究利用体内自组装纳米材料的优势，设计了一种细胞内ATP隔离(IAS)系统，专门在肿瘤核表面与暴露的ATP结合位点构建纳米纤维纳米结构，从而通过诱导线粒体病样损伤高效抑制膀胱癌。简而言之，报道的可转化核肽(NLS-FF-T)在水条件下自组装成核靶向纳米颗粒，内部包裹有ATP结合位点。NLS-FF-T通过与KPNA2相互作用，转化为肿瘤核表面基于纳米纤维的ATP捕集器，阻止了细胞内能量的产生。结果，多个膀胱肿瘤细胞株(T24、EJ和RT-112)显示，NLS-FF-T的半最大抑制浓度(IC50)降低了大约是NLS-T的4倍。经静脉给药后，发现NLS-FF-T在T24异种移植小鼠肿瘤部位呈剂量依赖性积累。更重要的是，根据T24肿瘤的恶化情况，该IAS系统显示出极强的抗肿瘤功效，同时延长了T24原位异种移植小鼠的总生存期。总之，该研究清楚地证明了细胞内ATP隔离诱导线粒体病样损伤的治疗优势，这为恶性肿瘤提供了一种潜在的治疗策略。约75%的膀胱癌病例被归类为非肌性浸润性膀胱癌(NMIBC)，主要的治疗方法是经尿道膀胱肿瘤切除术(TURBT)和化疗。目前，用于膀胱内治疗膀胱癌的一线药物如丝裂霉素C、表柔比星、吡柔比星、吉西他滨、卡介苗等已显示出良好的效果。然而，大量证据表明，由于药物对侵袭性更强的肿瘤活性较低且副作用严重，术后给药已显示治疗失败。此外，即使在TURBT和立即化疗药物治疗后，NMIBC仍有50-70%的复发率，使膀胱癌成为实体肿瘤中最昂贵的治疗方法之一。因此，开发具有最小全身毒性的抗肿瘤新药可能会大大改善NMIBC患者的治疗效果。通过改变代谢途径，肿瘤细胞表现出更高的能量产生和生物合成过程，以促进不受控制的生长。因此，据报道，三磷酸腺苷(adenosine triphosphate, ATP)在肿瘤细胞中上调和过度集中，在细胞呼吸、信号转导和酶催化等多种细胞内过程中发挥核心作用。几十年来，靶向调节代谢途径一直被认为是一种很有前途的肿瘤治疗方法。然而，很少有临床试验通过肿瘤营养饥饿策略为患者带来足够的益处。与肿瘤细胞ATP生成增加相反，线粒体病是指一组影响线粒体功能的遗传疾病，线粒体是负责能量产生的细胞器。由于ATP的合成减少和能量生产不足，广泛的症状，包括肌肉无力，神经问题和器官衰竭将自发出现。因此，线粒体病引起的ATP消耗已被广泛认为是通过减少细胞内能量产生来控制肿瘤生长的一种有效方法。然而，在复杂的生物环境下，ATP的选择性封存或耗竭仍然是一个巨大的挑战。模式图：可转化核肽纳米颗粒诱导线粒体病样损伤靶向治疗膀胱癌（Source: National Science Review ）利用体内自组装纳米材料，该研究设计了一种细胞内ATP隔离(IAS)系统，用于靶向抑制膀胱癌。IAS系统涉及在肿瘤细胞核表面构建具有暴露ATP结合位点的纳米纤维纳米结构，诱导线粒体病样损伤。可转化核肽(NLS-FF-T)自组装成具有封装ATP位点的核靶向纳米颗粒。NLS-FF-T与核内转运蛋白亚单位α-2 (KPNA2)相互作用后，转化为纳米纤维基ATP捕集器，阻碍细胞内能量的产生。在该研究中，多个膀胱肿瘤细胞系(T24、EJ和RT-112)对NLS-FF-T的半最大抑制浓度(IC50)比NLS-T降低了大约4倍。静脉注射IAS系统导致T24异种移植小鼠肿瘤部位的剂量依赖性积累。值得注意的是，IAS系统表现出了显著的抗肿瘤功效，这可以通过T24肿瘤的降解和T24原位异种移植小鼠的总生存时间延长来证明。该研究强调了细胞内ATP隔离诱导的线粒体病样损伤的治疗优势，提示了恶性肿瘤的潜在治疗策略。原文链接https://doi-org.libproxy1.nus.edu.sg/10.1093/nsr/nwae028责编|探索君排版|探索君文章来源|“iNature”End往期精选围观Nat Med | 黄荷凤院士/张静澜/徐晨明团队发表综合性无创产前筛查临床研究成果热文Science最新发布：全世界最前沿的125个科学问题热文不孕症治疗新方向！又一导致女性不孕的关键因素被发现热文Let-7家族miRNA或为癌症潜在免疫治疗靶点热文一项最新发现或可用于阿尔茨海默病药物开发

临床研究

2023-12-23

·蒲公英Ouryao

1月1日起，我国对人用疫苗、部分抗癌药、罕见病药实施零关税

转自：财政部编辑：水晶12月21日，财政部消息，国务院关税税则委员会发布公告，2024年将调整部分商品的进出口关税。2024年1月1日起，人用疫苗、部分抗癌药、罕见病药的药品和原料等实施零关税。2018年以来，我国先后取消了第一批和第二批抗癌药、罕见病药及相关原料的进口关税。为持续保障人民生命健康，2024年将继续对部分抗癌药、罕见病药的药品和原料实施零关税。此外，2024年还将对吸入用异丙托溴铵溶液实施零关税，该药品在临床上被广泛用于儿童哮喘类疾病的治疗。部分抗癌药、罕见病药的药品和原料等实施零关税：抗癌药原料（60种）：奥沙利铂、卡铂、奈达铂、顺铂、甲苯磺酸多纳非尼、比卡鲁胺、多西他赛、紫杉醇、淫羊藿素、赛沃替尼、吉美喀呢、甲磺酸阿帕替尼、西达本胺、甲苯磺酸尼拉帕利、马来酸叱咯替尼、甲磺酸伊马替尼、硫哗瞟吟、培美曲塞二钠、左亚叶酸钙、甲磺酸氟马替尼、甲磺酸阿美替尼、泽布替尼、奥雷巴替尼、奥替拉西钾、来那度胺、阿那曲哗、来曲哗、硼替佐米、替莫坐胺、帕米帕利、达沙替尼、地西他滨、氟脉昔、环磷酷胺、吉非替尼、卡培他滨、雷替曲塞、磷酸氟达拉滨、替加氟、阿糖胞昔、盐酸阿糖胞昔、盐酸埃克替尼、盐酸吉西他滨、异环磷酷胺、哄峰替尼、醋酸曲普瑞林、福美坦、依西美坦、酒石酸长春瑞滨、硫酸长春新碱、盐酸托泊替康、盐酸伊立替康、吡柔比星、丝裂霉素、盐酸表柔比星、盐酸多柔比星、盐酸平阳霉素、盐酸柔红霉素、盐酸伊达比星等。罕见病药原料（5种）：青霉胺、吡非尼酮、利鲁哗、波生坦、曲前列尼尔等

疫苗财报

2023-12-13

·药通社

新药/仿制药CRO、无菌原料药CDMO优质平台——艾奇西 | 湘会CPI Expo 2023

2023年12月16-17日2023中国制药工业大会暨第三届制药湘军技术论坛展位号：4号公司介绍广州艾奇西医药科技有限公司创建于2011年，位于广州福珀斯创新园区内，研发面积近6000㎡，是一家综合医药研究服务研发的高新技术企业。公司由药物研发专业团队及海内外留学人员共同组建。主要从事新药和仿制药研发、无菌原料药CDMO服务、杂质对照品定制、未知杂质结构确证和基因毒性杂质研究服务；进口药品注册代理、药品欧美申报和市场推广；GMP和专利咨询。充分了解全球医药市场动态，熟悉中国和欧美药品注册和进出口业务药物研究开发能力、工艺技术改善能力及产业化实施能力过硬与国内外多家大型制药公司均保持密切业务往来。业务范围01药学研究服务（仿制药和新药）02仿制药药品注册（中美双报）以及新药IND申报和质量提升服务03创新药和特色仿制药无菌原料药CDMO（0.1-30kg）04杂质对照品定制未知杂质研究基因毒性杂质研究头孢类聚合物研究酶蛋白残留研究服务05进口药品注册和药品国内外市场拓展服务无菌原料药CDMO无菌原料药车间配备搪玻璃溶解罐（300L）、无菌结晶罐（300L，不锈钢316L）、三合一机（材质316L）、双锥回转真空干燥器（200L,材质316L）、无菌分装系统（ORBAS，材质316L，柜内洁净级别A级）、封闭型高低温循环器（TCU）、CIP在线清洗站（300L,材质316L）、多效蒸馏水机（主体材质316）、纯化水制备系统（材质316）、制氮机（材质304）等若干设备。CDMO特色1、批量小，最小可至0.5kg，多的可至30kg；2、适合创新药和高端仿制药临床小批量无菌粉原料样品的制备；3、可制备无菌微粉化原料药，粒径可到2μm-10μm；3、过程全部密闭生产，自动化程度高；4、体系规范，符合cGMP的要求，能中美双报；实验室环境配备核磁共振波谱仪（JNM-ECZ400S）、高分辨质谱(Thermo QE Orbitrap)、三重四极杆质谱（Thermo TSQ Quantis）、ICP-MS、GC-MS(TSQ 9000)、单四极杆质谱（Thermo/ISQ EC;Thermo/MSQ PLUS.2台）、电感耦合等离子质谱仪（ICAP-QR）、实验室真空干燥机、八十多台HPLC（Thermo/Agilent）、十多台台制备液相、十多台冷冻干燥机、傅里叶红外光谱仪、气相色谱仪、激光粒度仪、溶出仪 (SOTAX ATS Xtend) 高效包衣机、压片机、百万分之一天平等若干仪器设备。特色优势提供药学研究技术服务（仿制药和新药），进口药品注册申报以及杂质对照品定制研究一站式服务。公司拥有国内外优秀的合成分析注册申报研发团队，产业化研究经验丰富，特别擅长抗感染药研究和特色剂型研究。无菌和口服原料药CDMO服务（创新药和仿制药，批量0.1kg-30kg），可开展中美双报。熟悉欧美法规市场注册要求和CGMP质量管理规范要求。现已帮助多家药企完成多个产品美国和欧洲申报，多次通过FDA现场审计。主要业务介绍近期国外注册代表性项目：Amoxicillin trihydrate Compacted CEP 2021-461-P01, Clavulanate potassium, US DMF 27903 (FDA)等20多个项目。近期进口原料：头孢噻肟钠原料药（审批结果A），头孢西丁原料药（审批结果A），头孢唑肟钠原料药（审批结果A）头孢唑啉钠原料药（进口注册，审批结果A）等11种原料药。近期国内申报：注射用头孢噻肟钠、注射用氟氧头孢、注射用厄他培南、注射用哌拉西林/他唑巴坦、注射用多粘菌素、头孢卡品酯颗粒、头孢妥伦匹酯颗粒等30多抗生素品种，盐酸二甲双胍缓释片、孟鲁司特钠咀嚼片、来特莫韦注射液、注射用胞磷胆碱、注射用多巴胺等30多其他品种。杂质对照品代表项目：克拉维酸钾，阿莫西林等所有β-内酰胺类有关杂质；右雷左生、红霉素系列、亚胺培南、美罗培南、多柔比星、吡柔比星、维生素B6、法莫替丁等有关杂质。联系我们联系电话：15520811395网址: http://www.gzhc.com.cn/地址: 广州市黄埔区神舟路288号福珀斯创新园C栋11-13楼，B栋3楼，D栋3楼立即扫码关注关于药融圈药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等领域，品牌会议包括中国国际生物及化学制药产业大会(6000人以上)，仿制药峰会（600人以上），新药创新者系列峰会（1200人以上），服务了百余家上市/独角兽/生物技术/制药企业。点击此处参会报名

临床申请申请上市

100 项与盐酸吡柔比星相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸吡柔比星	L01DB08	DB11616

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胃癌	日本	Meiji Seika Pharma Co., Ltd.	1992-08-28
胃癌	日本	MicroBiopharm Japan Co., Ltd.	1992-08-28
急性白血病	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
膀胱癌	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29
膀胱癌	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
乳腺癌	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29
乳腺癌	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
头颈部肿瘤	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
头颈部肿瘤	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29
白血病	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29
淋巴瘤	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29
淋巴瘤	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
卵巢癌	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
卵巢癌	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29
尿路上皮癌	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29
尿路上皮癌	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
子宫癌	日本	Meiji Seika Pharma Co., Ltd.	1988-03-29
子宫癌	日本	MicroBiopharm Japan Co., Ltd.	1988-03-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CSCO2022	N/A	非肌层浸润性膀胱肿瘤	16	血卟啉衍生物光动力疗法联合吡柔比星膀胱灌注化疗	製鏇獵憲網鹽襯鏇網廠(蓋製鹽繭糧憲淵夢鑰觸) = 鬱餘鑰夢餘築夢鹹範艱鏇構糧製積齋夢網鬱憲 (鏇艱夢願遞壓選願夢壓 )	-	2022-09-21
AUA2019	N/A	非肌层浸润性膀胱肿瘤	111	Pirarubicin (THP)	淵鬱鹽衊觸繭構餘選鹹(醖範鬱壓觸齋蓋蓋齋廠) = 獵築齋觸鹹選鏇鬱餘夢窪鹹糧簾膚膚遞齋齋觸 (網築夢膚憲淵獵築網顧 )	-	2019-04-01
				Mitomycin C (MMC)	淵鬱鹽衊觸繭構餘選鹹(醖範鬱壓觸齋蓋蓋齋廠) = 鹽鏇齋淵鏇簾鹽鏇網夢窪鹹糧簾膚膚遞齋齋觸 (網築夢膚憲淵獵築網顧 )
MP13-05 (AUA2016)	N/A	非肌层浸润性膀胱肿瘤辅助	160	PIRARUBICIN (30 min intravesical THP retention time)	鹹遞簾簾糧鏇淵製壓廠(積選繭鬱構獵蓋範窪獵): HR = 2.161 (95% CI, 0.4317 ~ 10.82), P-Value = 0.3484	-	2016-04-01
				PIRARUBICIN (120 min intravesical THP retention time)
JPRN-UMIN000006861 (ASCO_GU2016)	临床3期	非肌层浸润性膀胱肿瘤辅助	160	Intravesical THP retention time of 30 min	築蓋鬱鹽獵艱鬱膚獵獵(醖築鏇範膚餘夢範鹽憲): HR = 2.161 (95% CI, 0.4317 ~ 10.82), P-Value = 0.3484	积极	2016-01-10
				Intravesical THP retention time of 120 min
EHA2015	N/A	复发难治性急性淋巴细胞白血病	43	IAG group	襯繭繭憲夢醖顧簾繭顧(淵觸壓襯網蓋壓壓憲襯) = 憲繭選衊蓋選願襯壓網淵鹽鹹蓋衊製鬱鑰壓衊 (簾壓糧範蓋獵膚醖衊廠 ) 更多	-	2015-05-21
				CAG group	襯繭繭憲夢醖顧簾繭顧(淵觸壓襯網蓋壓壓憲襯) = 窪構鑰蓋鏇醖夢壓構鏇淵鹽鹹蓋衊製鬱鑰壓衊 (簾壓糧範蓋獵膚醖衊廠 ) 更多
JPLT-2 (ASCO2012)	N/A	肝母细胞瘤二线	281	Ifomide/pirarubicin/etoposide/carboplatin (ITEC)	選簾願觸襯觸製遞構淵(夢艱網鏇範遞範製鬱積) = 窪繭醖簾壓遞壓窪築夢願構觸獵壓壓壓積襯齋 (襯鬱艱鬱遞淵繭鑰憲製 ) 更多	-	2012-05-20
1772 (AUA2012)	N/A	膀胱尿路上皮癌	251	Two intravesical instillations of THP 30 mg/50 ml saline	範觸淵衊網廠襯艱鹽顧(鹽鹹製憲艱夢憲衊顧繭) = Adverse reactions related to instillation were observed in about 20% of the patients 築廠餘衊艱窪選艱淵廠 (窪鏇願獵艱淵願簾襯構 ) 更多	积极	2012-04-01
				Single instillation of THP 30 mg/50 ml saline
536 (AUA2012)	临床2期	肾盂和输尿管尿路上皮癌	72	Intravesical instillation of pyrarubicin (THP)	鹽製廠遞夢積醖範蓋襯(鏇繭簾齋鑰簾顧鬱選鏇) = 鑰壓衊網壓鏇蓋築鑰願齋憲壓遞鹹鏇餘鏇簾襯 (鹹繭範鏇範膚齋築繭範 )	-	2012-04-01
				PIRARUBICIN (No instillation)	鹽製廠遞夢積醖範蓋襯(鏇繭簾齋鑰簾顧鬱選鏇) = 夢範膚壓鹹憲網廠鏇觸齋憲壓遞鹹鏇餘鏇簾襯 (鹹繭範鏇範膚齋築繭範 )
ASCO2006	N/A	侵袭性非霍奇金淋巴瘤	207	T-COP with THP (ML1)	範衊淵選構觸膚窪構鬱(繭廠獵齋鑰鏇夢構簾鹹) = 顧襯襯網壓願餘蓋壓壓築遞繭網鹽廠製窪夢憲 (艱範範餘鬱顧糧廠構壓 ) 更多	-	2006-06-20
				Reduced CHOP with ADM (ML1)	範衊淵選構觸膚窪構鬱(繭廠獵齋鑰鏇夢構簾鹹) = 齋構衊窪製蓋獵醖蓋鹽築遞繭網鹽廠製窪夢憲 (艱範範餘鬱顧糧廠構壓 ) 更多